with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the

pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg

1998;228:508–517.

19. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal

gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma,

part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg

2002;236:355–366; discussion 366–368.

20. Farnell MB, Pearson RK, Sarr MG, et al. A prospective randomized trial comparing standard

pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in

resectable pancreatic head adenocarcinoma. Surgery 2005;138:618–630.

21. Nimura Y, Nagino M, Takao S, et al. Standard versus extended lymphadenectomy in radical

pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results

of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 2012;19:230–241.

22. Jang JY, Kang MJ, Heo JS, et al. A prospective randomized controlled study comparing outcomes

of standard resection and extended resection, including dissection of the nerve plexus and various

lymph nodes, in patients with pancreatic head cancer. Ann Surg 2014;259:656–664.

23. Traverso LW, Longmire WP Jr. Preservation of the pylorus in pancreaticoduodenectomy. Surg

Gynecol Obstet 1978;146:959–962.

24. Kozuschek W, Reith HB, Waleczek H, et al. A comparison of long term results of the standard

Whipple procedure and the pylorus preserving pancreatoduodenectomy. J Am Coll Surg 1994;

178:443–453.

25. Takada T, Yasuda H, Amano H, et al. Results of a pylorus-preserving pancreatoduodenectomy for

pancreatic cancer: a comparison with results of the Whipple procedure. Hepatogastroenterology

1997;44:1536–1540.

26. Tran KT, Smeenk HG, van Eijck CH, et al. Pylorus-preserving pancreaticoduodenectomy versus

standard Whipple procedure a prospective randomized multicenter analysis of 170 patients with

pancreatic and periampullary tumors. Ann Surg 2004;240:738–745.

27. Kooby D, Gillespie T, Bentrem D, et al. Left-sided pancreatectomy: a multicenter comparison of

laparoscopic and open approaches. Ann Surg 2008;248:438–446.

28. Palanivelu C, Jani K, Senthilnathan P, et al. Laparoscopic pancreaticoduodenectomy: technique and

outcomes. J Am Coll Surg 2007;205:222–230.

29. Kendrick ML, Cusati D. Total laparoscopic pancreaticoduodenectomy: feasibility and outcome in an

early experience. Arch Surg 2010;145:19–23.

30. Asbun HJ, Stauffer JA. Laparoscopic vs open pancreaticoduodenectomy: overall outcomes and

severity of complications using the accordion severity grading system. J Am Coll Surg

2012;215:810–819.

31. Chalikonda S, Aguilar-Saavedra JR, Walsh RM. Laparoscopic robotic-assisted

pancreaticoduodenectomy: a case-matched comparison with open resection. Surg Endosc

2012;26:2397–2402.

32. Zureikat AH, Moser AJ, Boone BA, et al. 250 Robotic pancreatic resections: safety and feasibility.

Ann Sur 2013;258:554–562.

33. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the

pancreas: 201 patients. Ann Surg 1995;221:721–733.

34. Richter A, Neidergethmann M, Sturm JW, et al. Long-term results of partial

pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.

World J Surg 2003;27:324–329.

35. Schmidt CM, Powell ES, Yiannoutsos CT, et al. Pancreaticoduodenectomy: a 20-year experience in

516 patients. Arch Surg 2004;139:718–725; discussion 725–727.

36. Sosa JA, Bowman HM, Gordon TA, et al. Importance of hospital volume in the overall management

of pancreatic cancer. Ann Surg 1998;228:320–330.

37. Winter JM. Cameron JL. Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic

cancer: a single-institution experience. J Gastrointest Surg 2006;10:1199–1210.

38. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and

chemotherapy following curative resection of pancreatic cancer. Cancer 1987;59:2006–2010.

1423

39. Kinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative

resection of cancer of the pancreas and periampullar region. Ann Surg 1999;230:776–782; discussion

782–784.

40. Neoptolemos JP, Stocken DD, Freiss H, et al. A randomized trial of chemoradiotherapy and

chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200–1210.

41. Regine WF, Winter KW, Abrams R, et al. RTOG 9704 a phase III study of adjuvant pre and post

chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. J Clin

Oncol 2006;24:18S.

42. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs. observation in

patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

JAMA 2007;297:267–277.

43. Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in

patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol

1997;15:928–937.

44. Hoffman JP, Lipsitz S, Pisansky T, et al. Phase II trial of preoperative radiation therapy and

chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern

Cooperative Oncology Group Study. J Clin Oncol 1998;16:317–323.

45. Pisters PW, Wolff RA, Janjan NA, et al. Preoperative paclitaxel and concurrent rapid-fractionation

radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and eventfree outcome. J Clin Oncol 2002;20:2537–2544.

46. Wolff RA, Evans DB, Crane CH. Initial results of preoperative gemcitabine-based chemoradiation

for resectable pancreatic Adenocarcinoma (abstract). Proc Am Soc Clin Oncol 2002;21:130a.

47. Talamonti MS, Small W Jr, Mulcahy MF, et al. A multi-institutional phase II trial of preoperative

full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic

carcinoma. Ann Surg Oncol 2006;13:150–158.

48. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for

patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26(21):3496–

3502.

49. Turrini O, Viret F, Moureau-Zabotto L, et al. Neoadjuvant 5 fluorouracil-cisplatin chemoradiation

effect on survival in patients with resectable pancreatic head adenocarcinoma: a ten-year single

institution experience. Oncology 2009;76(6):413–419.

50. Sohn TA, Lillemoe KD, Cameron JL, et al. Surgical palliation of unresectable periampullary

carcinoma in the 1990s. J Am Coll Surg 1999;188:658–666; discussion 666–659.

51. Sarr MG, Cameron JL. Surgical management of unresectable carcinoma of the pancreas. Surgery

1982; 91:123–133.

52. Lillemoe KD, Cameron JL, Hardacre JM, et al. Is prophylactic gastrojejunostomy indicated for

unresectable periampullary cancer? Ann Surg 1999;230:322–328; discussion 328–330.

53. Van Heek NT, De Castro SM, van Eijck CH, et al. The need for a prophylactic gastrojejunostomy for

unresectable periampullary cancer: a prospective randomized multicenter trial with special focus on

assessment of quality of life. Ann Surg 2003;238:894–902; discussion 902–905.

54. Lillemoe KD, Cameron JL, Kaufman HS, et al. Chemical splanchnicectomy in patients with

unresectable pancreatic cancer: a prospective randomized trial. Ann Surg 1993;217:447–455;

discussion 456–457.

55. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with

gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J

Clin Oncol 1997;15(6):2403–2413.

56. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU

refractory pancreas cancer. Ann Oncol 1996;7:347–353.

57. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic

cancer. NEJM 2011;364(19):1817–1825.

58. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel

plus gemcitabine. NEJM 2013;369(18):1691–1703.

1424